Clinical Trials

Blue Faery: The Adrienne Wilson Liver Cancer Association

AA

A A

Clinical Trials

Print Friendly, PDF & Email

Clinical trials are studies conducted on volunteers using investigational treatments or methods. The decision to enroll in a trial should be based on concrete information and eligibility depends on many factors. For more information about HCC clinical trials in your area, visit www.clinicaltrials.gov.

  • Discuss the advantages, disadvantages and side effects of treatment options with your doctor.
  • Ask your doctor about the possibility of using experimental therapies and eligibility to participate in clinical trials. If you want to participate in clinical trial, ask what is the phase of the trial.
  • Consider seeking a second opinion if your health insurance allows you the option to do so.


Liver Cancer Clinical Trials (featured listings)

Blue Faery does not endorse, sponsor or recommend any specific clinical trial. An asterisk indicates a paid listing.

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar)

This early phase I trial studies the side effects of autologous dendritic cells and a vaccine called Prevnar in treating patients with liver cancer that cannot be remove by surgery after undergoing standard high-dose external beam radiotherapy. Autologous dendritic cells are immune cells generated from patients' own white blood cells that are grown in a special lab and trained to stimulate the immune system to destroy tumor cells. A pneumonia vaccine called Prevnar may also help stimulate the immune system. Giving autologous dendritic cells and Prevnar to patients with live cancer after radiotherapy may help doctors determine if it is possible to stimulate the body's own immune system to fight against the tumor, and to see if this immune stimulation can be done safely.

Condition: Hepatocellular carcinoma
Intervention: Combination of external beam radiation therapy, pneumonia (Prevnar) vaccine and autologous dendritic cells
Phase: Phase 1
Study Type: Interventional (Clinical Trial)
Study Design: Single arm, open label
Primary Purpose: Treatment

For more information, contact Dr. Lewis Roberts, Director, Hepatobiliary Neoplasia Clinic

Email: Roberts.Lewis@mayo.edu

Website: https://www.mayo.edu/research/faculty/roberts-lewis-r-m-b-ch-b-ph-d/bio-00084430

Phone (507) 266-3239

Mayo Clinic
200 First Street SW
Rochester, MN 55905
United States
Map It


A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)*

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

Condition: Hepatocellular carcinoma
Intervention: Drug: Lenvatinib Biological: Pembrolizumab Drug: Oral Placebo Drug: IV Placebo Procedure: TACE
Phase: Phase 3
Study Type: Interventional
Study Design: Allocation: Randomized Intervention, Model: Parallel Assignment, Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment

For more information, email: Trialsites@merck.com

Medical Director
Merck Sharp & Dohme Corp.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
United States
Map It
Business Phone (888) 577-8839


A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma and Complete Radiological Response After Surgical Resection or Local Ablation (KEYNOTE-937)*

This study will evaluate the safety and efficacy of pembrolizumab (MK-3475) versus placebo as adjuvant therapy in participants with hepatocellular carcinoma (HCC) and complete radiological response after surgical resection or local ablation. The primary hypotheses of this study are that adjuvant pembrolizumab is superior to placebo with respect to: 1) recurrence-free survival (RFS) as assessed by blinded independent central review (BICR); and 2) overall survival (OS).

Condition: Hepatocellular carcinoma
Intervention: Biological: Pembrolizumab IV infusion of Pembrolizumab 200 mg. Other Names: KEYTRUDA® MK-3475 • Drug: Placebo IV infusion of 0.9% normal saline
Phase: Phase 3
Study Type: Interventional
Study Design: Allocation is Randomized, Intervention Model isParallel Assignment, Masking is Double (Participant, Investigator)
Primary Purpose: Treatment

For more information, email: Trialsites@merck.com

Medical Director
Merck Sharp & Dohme Corp.
2000 Galloping Hill Road
Kenilworth, New Jersey 07033
United States
Map It
Business Phone (888) 577-8839


A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)*

This is a randomized, double-blind, placebo-controlled, multicenter, global Phase III study to determine the efficacy and safety of transarterial chemoembolization (TACE) treatment in combination with durvalumab monotherapy or TACE given with durvalumab plus bevacizumab therapy compared to TACE therapy alone in patients with locoregional hepatocellular carcinoma not amenable to curative therapy.

Condition: Hepatocellular carcinoma
Intervention: Drug: Durvalumab Drug: Bevacizumab Other: Placebo Procedure: Transarterial Chemoembolization (TACE)
Phase: Phase 3
Study Type: Interventional
Study Design: Parallel Assignment
Primary Purpose: Treatment

For more information, email: information.center@astrazeneca.com

AstraZeneca Clinical Study Information Center
Business Phone: 1-877-240-9479


A Phase 2, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma*

CVM-1118 is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 with sorafenib for subjects with advanced hepatoma.

Condition: Hepatocellular carcinoma
Intervention: CVM-1118
Phase: Phase 2
Study Type: Interventional
Study Design: Single Group Assignment, Open Label
Primary Purpose: Treatment

For more information, email kdorr@sciquus.com

Kirsten Dorr, Senior Project Manager
Cell Phone: (858) 337-2927

SciQuus Oncology Inc.
4250 Executive Square, Suite 450
La Jolla, CA 92037
United States
Map It
Business Phone: (858) 642-0386


An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma*

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527 (Part 1), and to assess the safety and tolerability of H3B-6527 as a single agent administered orally (Part 2) in participants with advanced hepatocellular carcinoma (HCC).

Condition: Hepatocellular carcinoma
Intervention: Dose Escalation
Phase: Phase 1
Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Primary Purpose: Objective tumor response

For more information, email esi_medinfo@eisai.com.

H3 Biomedicine with Eisai Inc
300 Technology Square, 5th Floor
Cambridge, MA 02139
United States
Map It
Business Phone: (888) 274-2378


*Indicates a paid listing

Scroll Up